|
Aug 11
|
Non-metastatic Prostate Cancer Market Analysis and Forecast, 2023-2035 | J&J, Astellas, Bristol-Myers Squibb, Pfizer, Merck, Bayer, Sanofi, Clovis, AstraZeneca, AbbVie, and Boehringer Lead Innovations
|
|
Aug 8
|
Renal Transplant Therapeutics Market Insights, Competitive Landscape, and Forecast Report 2024-2032 | Calcineurin Inhibitors Dominate Renal Transplant Therapeutics Market
|
|
Jul 1
|
Is Alpha Cognition Inc. (ACOG) Outperforming Other Medical Stocks This Year?
|
|
Apr 3
|
Astellas Pharma and JFCR partner for oncology research
|
|
Feb 27
|
Astellas and MBC BioLabs Announce the Sixth Annual Astellas Future Innovator Prize
|
|
Feb 12
|
U.S. FDA Approves Expanded Label for Astellas' IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy
|
|
Feb 11
|
Pfizer/Astellas Tout Encouraging Data From Keytruda Combo Regime In Urothelial Cancer Showing 49% Reduction In Death Risk Vs. Chemo
|
|
Feb 10
|
Pfizer, Astellas Cite 'Durable Benefit' in More Trial Results of Padcev Plus Keytruda in Urothelial Cancer
|
|
Feb 10
|
Pfizer and Astellas’ PADCEV® (enfortumab vedotin-ejfv) plus KEYTRUDA® (pembrolizumab) Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer (la/mUC)
|